---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-233507"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2026-05-21T12:15:15+00:00"
generated_at: "2026-05-21T12:21:44.059341+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corbus appoints Nishant Saxena as first Chief Business Officer; schedules CRB-701 data call

## Summary
- Nishant Saxena appointed CBO; base salary $470K, 192,300 options and 58,300 RSUs as initial equity.
- Conference call on May 26 at 8:00 a.m. EDT to discuss updated Phase 1/2 CRB-701 data (data cut April 1).
- Upcoming milestones: initiation of registrational study of CRB-701 in second-line HNSCC and completion of CANYON-1 Phase 1b for CRB-913 (CB1 inverse agonist).
- Brent Pfeiffenberger granted 24,700 nonqualified options and 7,500 RSUs as initial board equity awards.

## SEC filing metadata
- accession: 0001193125-26-233507
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2026-05-21T12:15:15+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312526233507/0001193125-26-233507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312526233507/crbp-20260519.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-233507
- JSON: https://secwatch.observer/filing/0001193125-26-233507.json
- Plain text: https://secwatch.observer/filing/0001193125-26-233507.txt

## Key facts
- Executive change
  Brent Pfeiffenberger was appointed as Director at Corbus Pharmaceuticals Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: On May 19, 2026, the Compensation Committee granted Brent Pfeiffenberger the following initial equity awards under the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Incentive Plan (the “2024 Plan”) in connection with his appointment to the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595097/000119312526233507/0001193125-26-233507-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.